معرفی
Ralph Zinner, MD, is a Professor of Internal Medicine at the University of Kentucky College of Medicine and a key member of the Markey Cancer Center and Translational Oncology Research Program. His work focuses on advancing cancer therapy through clinical trials and translational research.
- Education: Doctor of Medicine (Georgetown University, 1993), Bachelor of Arts (University of California - Berkeley, 1986), Residency (Thomas Jefferson University, 1996), Postdoctoral Fellow (University of Texas Health Science Center, 1999)
Dr. Zinner specializes in lung and head and neck cancer, with a focus on KRAS/EGFR mutations, drug resistance, and precision oncology. He leads clinical trials integrating chemo-immune and molecularly targeted therapies to improve survival and reduce morbidity.
His recent publications highlight trends in computational modeling of drug resistance, digital health tools for rural cancer patients, and novel combination therapies like sapanisertib with carboplatin/paclitaxel.
- Active Grants (2025):
- A Phase III study of Rilvegostomig or Pembrolizumab in metastatic non-squamous NSCLC (AstraZeneca)
- Phase II induction therapy for unresectable Stage IIIA-C NSCLC (Bristol Myers Squibb)
